Sanjay Aggarwal

Dr. Sanjay Aggarwal is Apollo Therapeutics’ chief medical officer. Sanjay has spent over 20 years in the biopharmaceutical industry, including extensive experience in building and leading clinical development teams. He has a track record of taking drugs through development to successful regulatory approvals. He joined Apollo from Angiocrine Bioscience, a clinical stage cell and gene therapy company. Previously he was the architect of the Rezurock™ (belumosudil) phase 2 and 3 development program at Kadmon, leading to its FDA approval for chronic graft versus host disease. Before Kadmon he was the global development lead for Kyprolis® (carfilzomib) at Amgen, leading to its approval in multiple myeloma in the USA, EU and numerous other territories. Earlier in his career, he held positions of increasing responsibility in both biotech (Exelixis, Onyx Pharmaceuticals) and pharma (GSK, Novartis, Sanofi), overseeing development of early and late-stage assets across several therapeutic areas, and including roles in the USA, Europe and Asia-Pacific. Sanjay studied mathematics and medicine to earn his medical degree (MB BChir) from The University of Cambridge where he was a member of Queens’ College. He has an MBA from The University of Chicago Booth School of Business. Clinically, he trained in internal medicine and public health and is a member of the Royal College of Physicians (UK).